TR199900729T2 - A��lar - Google Patents
A��larInfo
- Publication number
- TR199900729T2 TR199900729T2 TR1999/00729T TR9900729T TR199900729T2 TR 199900729 T2 TR199900729 T2 TR 199900729T2 TR 1999/00729 T TR1999/00729 T TR 1999/00729T TR 9900729 T TR9900729 T TR 9900729T TR 199900729 T2 TR199900729 T2 TR 199900729T2
- Authority
- TR
- Turkey
- Prior art keywords
- lar
- sterol
- antigen
- relates
- immunologically active
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
- C12N2740/11034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Bu bulus sap, bir antijen, bir bagisikliksal aktif saponin fraksiyonu ile bir sterol içeren bir asi ile ilgilidir.This invention relates to an antigen, an immunologically active saponin fraction and a sterol containing a sterol.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9620795.6A GB9620795D0 (en) | 1996-10-05 | 1996-10-05 | Vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
TR199900729T2 true TR199900729T2 (en) | 1999-07-21 |
Family
ID=10800990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR1999/00729T TR199900729T2 (en) | 1996-10-05 | 1997-09-30 | A��lar |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP0939650A1 (en) |
JP (1) | JP2001501640A (en) |
KR (1) | KR20000048866A (en) |
CN (1) | CN1238696A (en) |
AR (1) | AR009958A1 (en) |
AU (1) | AU714930B2 (en) |
BR (1) | BR9711853A (en) |
CA (1) | CA2267191A1 (en) |
CO (1) | CO4910170A1 (en) |
CZ (1) | CZ116799A3 (en) |
GB (1) | GB9620795D0 (en) |
HU (1) | HUP9904549A3 (en) |
IL (1) | IL128985A0 (en) |
NO (1) | NO991524L (en) |
NZ (1) | NZ334734A (en) |
PL (1) | PL332633A1 (en) |
TR (1) | TR199900729T2 (en) |
WO (1) | WO1998015287A1 (en) |
ZA (1) | ZA978868B (en) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE435661T1 (en) * | 1997-08-29 | 2009-07-15 | Antigenics Inc | COMPOSITIONS CONTAINING ADJUVANT QS-21 WITH POLYSORBATE OR CYCLODEXTRIN AS AID |
GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
GB9817052D0 (en) * | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
ES2284287T3 (en) | 1998-10-16 | 2007-11-01 | Glaxosmithkline Biologicals S.A. | ADJUSTMENT SYSTEMS AND VACCINES. |
AU769539B2 (en) | 1999-01-29 | 2004-01-29 | Zoetis Services Llc | Adjuvants for use in vaccines |
GB9909077D0 (en) * | 1999-04-20 | 1999-06-16 | Smithkline Beecham Biolog | Novel compositions |
US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
DK1187629T3 (en) | 1999-04-19 | 2005-01-17 | Glaxosmithkline Biolog Sa | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
GB9921147D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
DE60018769T2 (en) | 1999-09-24 | 2005-08-04 | Nihon Nohyaku Co., Ltd. | AROMATIC DIAMIDE DERIVATIVES OR ITS SALTS, CHEMICALS FOR AGRICULTURE / GARDENING AND METHOD OF THEIR USE |
JP4540033B2 (en) | 1999-10-22 | 2010-09-08 | サノフィ パストゥール リミテッド | Methods for inducing and / or enhancing immune responses against tumor antigens |
EP1239876B1 (en) * | 1999-11-19 | 2008-07-30 | Csl Limited | Hcv vaccine compositions |
US6905712B2 (en) | 1999-12-08 | 2005-06-14 | Statens Veterinarmedicinska Anstalt | Vaccine adjuvants comprising ginseng plant extract and added aluminum salt |
AU2243801A (en) * | 1999-12-08 | 2001-06-18 | Statens Veterinarmedicinska Anstalt | Vaccine adjuvants comprising ginseng plant extract and added aluminium salt |
US7851212B2 (en) | 2000-05-10 | 2010-12-14 | Sanofi Pasteur Limited | Immunogenic polypeptides encoded by MAGE minigenes and uses thereof |
KR100831139B1 (en) | 2000-10-18 | 2008-05-20 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Vaccines |
WO2002067983A1 (en) * | 2001-02-23 | 2002-09-06 | Glaxosmithkline Biologicals S.A. | Novel vaccine |
US20040071734A1 (en) * | 2001-02-23 | 2004-04-15 | Nathalie Garcon | Novel vaccine |
GB0110431D0 (en) * | 2001-04-27 | 2001-06-20 | Glaxosmithkline Biolog Sa | Novel compounds |
GB0123580D0 (en) * | 2001-10-01 | 2001-11-21 | Glaxosmithkline Biolog Sa | Vaccine |
EP1523557A2 (en) | 2002-07-24 | 2005-04-20 | Intercell AG | Antigens encoded by alternative reading frame from pathogenic viruses |
US7378234B2 (en) | 2002-09-13 | 2008-05-27 | Intercell Ag | Method for isolating hepatitis C virus peptides |
CA2502268A1 (en) | 2002-10-23 | 2004-05-06 | Glaxosmithkline Biologicals S.A. | Methods for vaccinating against malaria |
US7704514B2 (en) | 2003-03-24 | 2010-04-27 | Intercell Ag | Vaccines |
EP1608401A1 (en) * | 2003-03-24 | 2005-12-28 | Intercell AG | Use of alum and a th1 immune response inducing adjuvant for enhancing immune respones |
GB0417494D0 (en) | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
GB0503337D0 (en) | 2005-02-17 | 2005-03-23 | Glaxosmithkline Biolog Sa | Compositions |
GB0513421D0 (en) | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
GB0519871D0 (en) | 2005-09-30 | 2005-11-09 | Secr Defence | Immunogenic agents |
US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
US10842867B2 (en) | 2005-11-04 | 2020-11-24 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
TWI457133B (en) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | Novel composition |
GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
PT3017827T (en) | 2005-12-22 | 2019-01-28 | Glaxosmithkline Biologicals Sa | Pneumococcal polysaccharide conjugate vaccine |
MY148405A (en) | 2006-03-30 | 2013-04-30 | Glaxosmithkline Biolog Sa | Immunogenic composition |
JP5592110B2 (en) | 2006-07-18 | 2014-09-17 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Malaria vaccine |
EP2040744B1 (en) | 2006-07-25 | 2016-03-09 | The Secretary of State for Defence | Live vaccine strains of francisella |
AU2007322424B2 (en) * | 2006-11-20 | 2013-05-16 | Duecom | Use of lipid containing particles comprising quillaja saponins for the treatment of cancer |
PT2137210T (en) | 2007-03-02 | 2017-01-09 | Glaxosmithkline Biologicals Sa | Novel method and compositions |
RS54349B1 (en) | 2007-06-26 | 2016-02-29 | Glaxosmithkline Biologicals S.A. | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
TR201802221T4 (en) | 2007-08-13 | 2018-03-21 | Glaxosmithkline Biologicals Sa | Vaccines. |
WO2009117035A1 (en) | 2007-12-19 | 2009-09-24 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Soluble forms of hendra and nipah virus f glycoprotein and uses thereof |
GB0815872D0 (en) | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
GB0900455D0 (en) | 2009-01-13 | 2009-02-11 | Secr Defence | Vaccine |
GB0901423D0 (en) | 2009-01-29 | 2009-03-11 | Secr Defence | Treatment |
GB0901411D0 (en) | 2009-01-29 | 2009-03-11 | Secr Defence | Treatment |
EP3173097A3 (en) | 2009-02-10 | 2017-07-12 | Seqirus UK Limited | Influenza vaccines with reduced amounts of squalene |
US20120058149A1 (en) * | 2009-03-05 | 2012-03-08 | Mccloskey Jenny Colleen | Treatment of infection |
GB0906234D0 (en) | 2009-04-14 | 2009-05-20 | Secr Defence | Vaccine |
GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
WO2011117408A1 (en) | 2010-03-26 | 2011-09-29 | Glaxosmithkline Biologicals S.A. | Hiv vaccine |
US20130259948A1 (en) | 2010-09-21 | 2013-10-03 | National Institute Of Immunology | Spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles |
US9168292B2 (en) | 2010-09-27 | 2015-10-27 | Crucell Holland B.V. | Heterologous prime boost vaccination regimen against malaria |
MX2014002769A (en) | 2011-09-16 | 2014-06-11 | Ucb Pharma Sa | Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile. |
US20130122038A1 (en) | 2011-11-14 | 2013-05-16 | The United States Of America As Represented By The Secretary Of The Department | Heterologous prime-boost immunization using measles virus-based vaccines |
WO2015092710A1 (en) | 2013-12-19 | 2015-06-25 | Glaxosmithkline Biologicals, S.A. | Contralateral co-administration of vaccines |
WO2018037045A1 (en) | 2016-08-23 | 2018-03-01 | Glaxosmithkline Biologicals Sa | Fusion peptides with antigens linked to short fragments of invariant chain (cd74) |
GB201614799D0 (en) | 2016-09-01 | 2016-10-19 | Glaxosmithkline Biologicals Sa | Compositions |
US11466292B2 (en) | 2016-09-29 | 2022-10-11 | Glaxosmithkline Biologicals Sa | Compositions and methods of treatment |
JP7136777B2 (en) * | 2016-12-07 | 2022-09-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | new process |
GB201620968D0 (en) | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
IE20190085A3 (en) * | 2017-05-30 | 2023-07-19 | Glaxosmithkline Biologicals Sa | Novel methods for manufacturing an adjuvant |
GB201721069D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B Immunisation regimen and compositions |
GB201721068D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B immunisation regimen and compositions |
MX2020013553A (en) | 2018-06-12 | 2021-02-26 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides. |
JP2021533162A (en) | 2018-08-07 | 2021-12-02 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Processes and vaccines |
EP3897846A1 (en) | 2018-12-21 | 2021-10-27 | GlaxoSmithKline Biologicals SA | Methods of inducing an immune response |
CA3132601A1 (en) | 2019-03-05 | 2020-09-10 | Glaxosmithkline Biologicals Sa | Hepatitis b immunisation regimen and compositions |
WO2023056117A1 (en) * | 2021-10-02 | 2023-04-06 | Massachusetts Institute Of Technology | Synergistic combination of alum and non-liposome, non-micelle particle vaccine adjuvants |
WO2024133160A1 (en) | 2022-12-19 | 2024-06-27 | Glaxosmithkline Biologicals Sa | Hepatitis b compositions |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL9002314A (en) * | 1990-10-23 | 1992-05-18 | Nederlanden Staat | IMMUNOGENE COMPLEXES, IN PARTICULAR ISCOMS. |
BR9206310A (en) * | 1991-07-25 | 1995-04-25 | Idec Pharma Corp | Induction of cytotoxic responses of T lymphocytes. |
JP4129544B2 (en) * | 1993-03-29 | 2008-08-06 | ファイザー・インク | Multi-component clostridial vaccine using saponin adjuvant |
UA56132C2 (en) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine |
-
1996
- 1996-10-05 GB GBGB9620795.6A patent/GB9620795D0/en active Pending
-
1997
- 1997-09-30 WO PCT/EP1997/005578 patent/WO1998015287A1/en not_active Application Discontinuation
- 1997-09-30 IL IL12898597A patent/IL128985A0/en unknown
- 1997-09-30 CZ CZ991167A patent/CZ116799A3/en unknown
- 1997-09-30 HU HU9904549A patent/HUP9904549A3/en unknown
- 1997-09-30 AU AU47812/97A patent/AU714930B2/en not_active Ceased
- 1997-09-30 JP JP10517196A patent/JP2001501640A/en active Pending
- 1997-09-30 TR TR1999/00729T patent/TR199900729T2/en unknown
- 1997-09-30 BR BR9711853A patent/BR9711853A/en not_active Application Discontinuation
- 1997-09-30 NZ NZ334734A patent/NZ334734A/en unknown
- 1997-09-30 EP EP97910430A patent/EP0939650A1/en not_active Withdrawn
- 1997-09-30 KR KR1019990702874A patent/KR20000048866A/en not_active Application Discontinuation
- 1997-09-30 PL PL97332633A patent/PL332633A1/en unknown
- 1997-09-30 CA CA002267191A patent/CA2267191A1/en not_active Abandoned
- 1997-09-30 CN CN97180166A patent/CN1238696A/en active Pending
- 1997-10-03 CO CO97057863A patent/CO4910170A1/en unknown
- 1997-10-03 ZA ZA978868A patent/ZA978868B/en unknown
- 1997-10-03 AR ARP970104569A patent/AR009958A1/en unknown
-
1999
- 1999-03-29 NO NO991524A patent/NO991524L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU714930B2 (en) | 2000-01-13 |
IL128985A0 (en) | 2000-02-17 |
NZ334734A (en) | 2000-05-26 |
PL332633A1 (en) | 1999-09-27 |
CZ116799A3 (en) | 1999-08-11 |
EP0939650A1 (en) | 1999-09-08 |
CO4910170A1 (en) | 2000-04-24 |
KR20000048866A (en) | 2000-07-25 |
WO1998015287A1 (en) | 1998-04-16 |
NO991524D0 (en) | 1999-03-29 |
GB9620795D0 (en) | 1996-11-20 |
CN1238696A (en) | 1999-12-15 |
NO991524L (en) | 1999-03-29 |
AR009958A1 (en) | 2000-05-17 |
JP2001501640A (en) | 2001-02-06 |
HUP9904549A3 (en) | 2001-06-28 |
CA2267191A1 (en) | 1998-04-16 |
BR9711853A (en) | 1999-08-24 |
HU9904549A (en) | 2000-05-28 |
ZA978868B (en) | 1999-04-06 |
AU4781297A (en) | 1998-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR199900729T2 (en) | A��lar | |
TR199701252T1 (en) | Networks containing a saponin and a sterol. | |
TR199900639T2 (en) | Olanzapin dihydrate D. | |
DE69840025D1 (en) | ASSOCIATED ANSWERS | |
TR200000740T2 (en) | Methods and compositions for whitening teeth. | |
TR200000573T2 (en) | Poly-coated paper compounds | |
ITTO930789A1 (en) | FIXING DEVICE FOR A SEAT COVER, PROCEDURE THAT USES THIS DEVICE AND SEAT OBTAINED IN ACCORDANCE WITH THIS PROCEDURE. | |
DE69010114D1 (en) | Aligned slide holding device and slide arrangement therefor. | |
TR199600097A2 (en) | Single lever mixing valve with an improved valve. | |
DE68918701D1 (en) | Grinding device and system therefor. | |
BR9707211A (en) | Capsule opening device for use in a powder inhaler | |
DE69719775D1 (en) | Thrombin inhibitoren | |
DE69006029D1 (en) | Hydrocarbon fuel compositions and additives therefor. | |
FR2733250B1 (en) | ANTI-GP130 MONOCLONAL ANTIBODIES, AND USES THEREOF | |
TR199802486T2 (en) | Zarflanm�� e�ya. | |
NO892595L (en) | PERFORING, TESTING AND SAMPLING TOOLS. | |
TR199800214T1 (en) | Allergen-XCD32 fusion proteins. | |
DE68919101D1 (en) | Gas shut-off device. | |
NO892760D0 (en) | SAFETY VALVE TESTING DEVICE. | |
NO901265L (en) | GAS AND ODOR ABSORBING DEVICE. | |
DE68914591D1 (en) | Actuating lever and operating device. | |
TR200001227T2 (en) | Fuel composition and mixture. | |
TR199700065A3 (en) | Combined punch and staple. | |
IT1227234B (en) | TEXTILE CUTTING AND RETENTION DEVICE. | |
NO990581L (en) | Method and Materials for Modifying Complement Activation |